



## CLAIMS

1. A method of treating an eye condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,




2. The method of Claim 1 wherein the eye condition is selected from the group consisting of diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, epidemic keratoconjunctivitis, Vitamin A deficiency, contact lens overwear, atopic keratitis, superior limbic keratitis, pterygium keratitis sicca, myopia, Terrien's marginal degeneration, marginal keratolysis, radial keratotomy, macular degeneration, post-laser complications, chronic retinal detachment; optic pits, hyperviscosity syndromes, chronic uveitis, chronic vitritis, ocular neovascular disease, age-related macular degeneration, presumed ocular histoplasmosis, infections causing retinitis or choroiditis, proliferative vitreoretinopathy, scleritis, Eales' disease, Best's disease, and trachoma.
3. The method of Claim 1 wherein the amount administered is between approximately 0.1 and approximately 300 mg/kg/day.

4. The method of Claim 3 wherein the amount administered is between approximately 0.5 and approximately 50 mg/kg/day.
5. The method of Claim 4 wherein the amount administered is between approximately 1 and approximately 10 mg/kg/day.
- 5 6. The method of Claim 1 wherein the compound is administered in the form of a tablet or capsule.
- 10 7. The method of Claim 1 wherein the compound is administered in the form of a lozenge, a cachet, a solution, a suspension, an emulsion, a powder, an aerosol, a suppository, a spray, a pastille, an ointment, a cream, a paste, a foam, a gel, a tampon, or a pessary.
8. The method of Claim 1 wherein the administration is oral, parenteral, transdermal, or topical.
- 9 The method of Claim 1 wherein the administration is sublingual, buccal, rectal, vaginal, or nasal.
- 15 10. A method of treating a non-tumor blood condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,




11. The method of Claim 10 wherein the blood condition is selected from the group consisting of vein occlusion, artery occlusion, carotid obstructive disease, polyarteritis, atherosclerosis, Osler-Weber-Rendu disease, and sickle cell anemia.

5 12. A method of treating an ulcerative disease associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,




10 13. The method of Claim 12 wherein the ulcerative disease is selected from the group consisting of bacterial ulcers, fungal ulcers, Mooren's ulcer, Wegener's sarcoidosis, Stevens-Johnson disease, Behcet's disease, pemphigoid, and ulcerative colitis.

15 14. A method of treating a skin condition associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,



15. The method of Claim 14 wherein the skin condition is selected from the group consisting of acne, rosacea, chemical burns, and psoriasis.

5 16. A method of treating an immune disease associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,




10


17. The method of Claim 16 wherein the immune disease is selected from the group consisting of rheumatoid arthritis, systemic lupus,

acquired immune deficiency syndrome, and osteoarthritis.


18. A method of treating an infection associated with angiogenesis in a human or animal comprising administering to said human or animal an angiogenesis inhibiting amount of EM-138,



19. The method of Claim 18 wherein the infection is selected from the group consisting of *Herpes simplex* infections, *Herpes zoster* infections, *Mycobacteria* infections, protozoan infections, toxoplasmosis, syphilis, and Bartonellosis.
20. A method for inhibiting undesired angiogenesis in a human or animal wherein the angiogenesis is associated with a condition selected from the group consisting of trauma, sjogren's syndrome, phlyctenulosis, sarcoid, pseudoxanthoma elasticum, Stargardt's disease, Paget's disease, Lyme's disease, par planitis, pyogenic granulomas, and lipid degeneration comprising administering to the human or animal an angiogenesis inhibiting amount of EM-138,



21. A method of inhibiting undesired angiogenesis in a human or animal wherein the angiogenesis is associated with a condition selected from the group consisting of Crohn's disease and chronic inflammation comprising administering to the human or animal an angiogenesis inhibiting amount of EM-138,



22. A method of inhibiting undesired angiogenesis in a human or animal wherein the angiogenesis is associated with abnormal proliferation of fibrovascular or fibrous tissue comprising administering to the human or animal an angiogenesis inhibiting

10026037 121901

000A2

amount of EM-138,

